The lawsuit was initially filed under the qui tam, or whistle-blower, provisions of the False Claims Act, and the government intervened in the case in April 2013.
The lawsuit specifically alleged Novartis paid kickbacks to pharmacies for recommending Exjade, an iron chelation drug, and Myfortic, an anti-rejection drug for kidney transplant recipients.
To resolve the case, Novartis agreed to pay $370 million to settle federal and state false claims allegations. Of the $370 million, nearly $286.9 million will be paid to the federal government, and about $83.1 million will be paid to the settling states. Novartis also agreed to forfeit $20 million as proceeds from the scheme under the civil forfeiture statute.
More articles on healthcare industry lawsuits:
6 latest healthcare industry lawsuits, settlements
Blue Shield of California sues ex-executive who led public attack against it
7 latest False Claims Act settlements
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
